Tarsus Pharmaceuticals, Inc.
TARS
Rank in Stocks
#4648
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Share Price
$69.68
Last synced: 2026-10-19
Market Cap
$3.26B
Change (1 day)
2.36%
Change (1 year)
-2.13%
Country
US
Trade Tarsus Pharmaceuticals, Inc. (TARS)
Category
Healthcare
Number of shares outstanding for Tarsus Pharmaceuticals, Inc. (TARS)
Number of shares outstanding as of June 2026: 43.39M
According to Tarsus Pharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 43.39M. At the end of December 2023 the company had 29.38M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Tarsus Pharmaceuticals, Inc. (TARS) from 2018 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 43.39M | 15.39% |
| 2024 | 37.60M | 27.98% |
| 2023 | 29.38M | 19.35% |
| 2022 | 24.62M | 19.78% |
| 2021 | 20.55M | 1.14% |
| 2020 | 20.32M | 4.17% |
| 2019 | 19.51M | 355.26% |
| 2018 | 4.29M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 485.11% |
US
|
|
| 396.00M | 812.58% |
US
|
|
| 478.91M | 1,003.65% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 43.31% |
NL
|
